INTRODUCTION

Rubella, sometimes called German measles, is a serious disease that used to be common in the United States. Thanks to the vaccine, rubella was declared eliminated from the United States in 2004 — meaning it’s no longer constantly present in this country. But, each year, a few Americans who live or travel outside of the country report getting sick from rubella.

There are 2 vaccines that can prevent rubella:

• The MMR vaccine protects children and adults from rubella measles, and mumps
• The MMRV vaccine protects children from rubella, measles, mumps, and chickenpox

IMPORTANCE OF VACCINE

Rubella is a contagious disease caused by a virus. It can lead to serious complications, especially for unborn babies. If a pregnant woman gets rubella, she can lose her baby. Babies born to mothers who had rubella can have birth defects that last a lifetime.

Rubella is still common in other countries. People can get the disease when they travel-and spread it to people who aren’t vaccinated when they come home.

Getting vaccinated is the best way to prevent rubella. And when enough people get vaccinated against rubella, the entire community is less likely to get it. So when you and your family get vaccinated, you help keep yourselves and your community healthy.

WHO NEED TO GET VACCINATED

Children need 2 doses of the vaccine at the following ages:

• 12 through 15 months for the first dose
• 4 through 6 years for the second dose (or sooner as long as it’s 28 days after the first dose)

SIDE EFFECTS

Side effects are usually mild and go away in a few days. They may include:

• Fever
• Mild rash
• Swollen glands in the cheeks or neck

Less common side effects of the rubella vaccine include:

• Pain or stiffness in the joints, usually in women (up to 1 person out of 4)
• Seizures (sudden, unusual movements or behavior) from having a high fever (about 1 out of every 3,000 doses)
• Temporary (short-term) low platelet count (about 1 out of every 30,000 doses)

CONCLUSION

Our Journal is planning to release a year end special issue has announced almost 50% discount on article publication charges to celebrate its journey for publishing articles within the short time.

 A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing.

Manuscripts can be forwarded to the Editorial Office at autoimmunedis@eclinicalsci.com

Media Contact:
John Kimberly
Editorial Manager
Journal of Vaccines & Vaccination
Email: jvv@scholarlypub.com